Every seasoned secondary buyer knows about the right of first refusal. ROFR gets most of the attention because it can pull a buyer out of a deal entirely. But there is a quieter killer that sits one step earlier in the process: company consent to transfer.

Consent rights are not ROFR. They do not give the company the right to buy your shares at your agreed price. They give the company the right to simply say no — or, more commonly, to say nothing at all for 30, 60, or 90 days while your deal sits in a queue.

Where consent requirements come from

Company consent clauses live in two places: the stockholders' agreement (or limited liability company agreement, if the company is structured as an LLC) and the underlying equity plan documents for option or RSU holders. They are not uniform. One company might require board approval for any transfer above a threshold. Another might delegate consent authority to the CFO or general counsel, who processes requests in batches. A third might have a blanket prohibition on transfers to competitors, which requires someone to actually verify who the buyer is before signing off.

The result is that consent timelines vary enormously across issuers — and they are rarely disclosed in advance. A seller who closes three deals with one company in a given year may believe they know the process. A new buyer transacting in the same name for the first time has no basis for that expectation.

Board approval
A full board vote is required for each individual transfer — the slowest path, used by companies that want maximum control over their cap tables.
Officer delegation
A designated officer (often the CFO or GC) holds approval authority. Faster, but dependent on that person's bandwidth and deal prioritization.
Transfer agent protocol
Some late-stage companies use a third-party transfer agent with a defined SLA for consent decisions. The most predictable timeline, usually 10–20 business days.
Blanket restriction with narrow carve-outs
Transfer is prohibited except to defined permitted transferees (family trusts, estate planning vehicles). Secondary buyers typically fall outside these carve-outs and need affirmative consent.

Why consent is distinct from ROFR — and often harder to manage

ROFR has a known clock. Under most agreements, the company (and sometimes existing investors) has a defined window — typically 30 days — to exercise. If no one exercises, the transfer proceeds. Silence is eventually a green light.

Consent does not work that way. Many agreements require affirmative written consent before a transfer can close. Silence is not consent. If the company does not respond, the deal simply does not close — and the seller may be in breach if they attempt to transfer without it. This creates real leverage for companies that prefer to slow-walk or delay secondary liquidity without formally refusing it.

ROFR has a clock. Consent often does not. The absence of a response deadline is one of the most overlooked risks in a secondary transfer agreement.

There is also a practical difference in who bears the burden. With ROFR, the seller and buyer can often proceed in parallel with documentation preparation while the ROFR window runs. With consent, some companies will not even begin reviewing a transfer request until the final purchase agreement is in agreed form — meaning the buyer has spent legal fees on a deal that has not yet cleared its first gate.

Common reasons consent is delayed or withheld

Companies withhold or delay consent for reasons that range from the procedural to the strategic. Understanding which category you are in early determines whether you can solve the problem or need to walk away.

  • Cap table hygiene: the company is mid-cleanup on its shareholder registry and is not processing any transfers until the audit is complete.
  • Pending financing: the company is in a quiet period ahead of a primary round and does not want secondary pricing data setting a market before terms are fixed.
  • Buyer identity concern: the prospective buyer is a known competitor, a foreign national subject to CFIUS screening, or an entity the company does not recognize. Some companies run light KYC on buyers before approving transfers.
  • Holder count: the company is managing its Section 12(g) threshold — once a private company has more than 2,000 holders of record (or 500 non-accredited investors), it triggers SEC reporting obligations. A company approaching that limit may pause transfers.
  • Strategic optionality: the company simply prefers less secondary market activity ahead of a tender offer or structured liquidity event it is planning internally.

What buyers and sellers should do before signing a term sheet

The most effective intervention is the earliest one. Before a buyer and seller agree on price and execute a letter of intent, both parties should attempt to understand the issuer's current consent posture. This does not mean approaching the company directly — doing so prematurely can trigger exactly the friction you are trying to avoid. It means working with a marketplace that has pattern data on that issuer's transfer history.

A few questions worth confirming before any term sheet is signed:

  1. Does the transfer agreement require affirmative written consent, or does ROFR waiver serve as implicit approval for the transfer to proceed?
  2. Is there a defined response deadline for the company's consent decision, and what happens if it lapses?
  3. Does the company's current policy require board-level approval or has it been delegated?
  4. Has the company processed secondary transfers in the past 12 months, and at what volume?
  5. Is there a pending primary round, tender offer, or restructuring that might cause the company to pause transfer approvals?

None of these questions can always be answered with certainty. But the quality of the answers available to you before you sign is a meaningful signal about deal execution risk.

How structure affects consent exposure

The choice between a direct share transfer and an SPV (special purpose vehicle) structure does not eliminate company consent requirements, but it can change who bears the burden and when. In a direct transfer, the buyer is taking title to the shares and becoming a holder of record — the company must approve that specific new holder. In an SPV structure, the seller transfers interests in the underlying shares to the SPV, and the SPV's membership interests are then sold to investors. Depending on the issuer's transfer documents, the SPV itself may be the only entity that needs to be approved as a holder of record, with beneficial interest transfers among SPV investors not requiring additional company consent.

This is not a loophole — it is a recognized structural feature. But it only works if the original SPV formation and transfer were properly approved. An SPV built on a transfer that never received valid company consent is sitting on a defective chain of title, which creates risk at the exit event when the company processes distributions.

An SPV built on a transfer that never received valid company consent carries defective title — a risk that may not surface until an exit distribution is processed years later.

The practical takeaway for both sides

Sellers should treat company consent as a first-order constraint, not an afterthought. If you are working with a marketplace that does not surface issuer-level transfer history before you sign a term sheet, you are pricing execution risk without data.

Buyers should build consent timelines into their hold assumptions. A deal that takes 90 days to close instead of 30 is not just an inconvenience — it is capital deployed in a side pocket with no return during the wait, and it may affect your carry basis date for tax purposes depending on how the holding period is measured.

At Limen Markets, we track consent history by issuer and build that data into our pre-execution workflow. Before you submit an indication of interest on any of our 28 listed names, you can ask our team for a plain-language summary of known transfer friction for that issuer. Start on the marketplace.